Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy
LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the release of preliminary data relating to the use of a novel cell therapy approach in controlling human immunodeficiency virus (HIV) in humans. Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences and Director of the Seraph Research Institute (SRI), presented the findings at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Presentation can be found at https://www.enochianbio.com/about-us/collaborations/
A 54-year-old man, diagnosed with HIV in 1986, had persistent HIV detected in his blood, despite antiretroviral therapy. With approval from an Institutional Review Board, this single patient was treated with a novel cellular therapy of natural killer (NK) and gamma delta T-cells (GDT) – a small subset of immune cells that can be infected with HIV but could also be a key factor in controlling the virus. The NK and GDT cells were collected from a person who does not have HIV. Because the patient stopped antiviral treatment and received some supportive medication before the cellular therapy, the level of HIV initially increased, as expected.
However, HIV levels began to decline after approximately three weeks, and after 100 days dropped below the detection level of routinely used blood tests (20 copies/ml). HIV levels in the patient’s blood have remained at or below detection for an additional 255 days, all while the patient has not been taking antiviral medication.
This innovative cell therapy could be a potential strategy to achieve a “functional cure” for HIV. This could potentially allow persons living with HIV to stop antiviral treatment for extended periods of time. Dr. Gumrukçu and SRI are currently pursuing a regulatory pathway with the FDA to study the approach in more patients. Enochian BioSciences holds the exclusive license for the proprietary technology.
Dr. Mark Dybul, a prominent global HIV expert and Executive Vice Chair of Enochian BioSciences said, “As an HIV researcher, clinician and former leader of large, global HIV treatment programs, I am excited by these results. Although antiviral treatment is very effective, it is expensive and some patients cannot, or do not want to receive it. This, combined with the fact that access to antiviral treatments is limited, creates a significant unmet medical need. While the findings presented are preliminary and in one person with HIV, I’m hopeful that with further testing in larger patient populations, SRI’s novel cell therapy approach could one day be an alternative HIV treatment to many.”
About Enochian BioSciences, Inc.
Enochian BioSciences, Inc. is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. The company’s gene-modified cell therapy platform can be applied to multiple indications, including HIV/AIDS and Oncology. For more information, please visit www.enochianbio.com
About Seraph Research Institute (SRI)
Seraph Research Institute is a Los Angeles-based non-profit research institution, which runs basic science, translational and clinical research in pursuit of cures and effective treatments for chronic viral infections, cancers, and genetic disorders. For more information, please visit Seraphinstitute.org
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences’ most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The findings in this press release are preliminary and based on one person. There is no assurance the findings will result in an effective alternative treatment for HIV. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
algoWatt and Italeaf sign the Recovery Agreement with the Sole Representative of the Bondholders22.6.2021 19:46:02 CEST | Press release
algoWatt and Italeaf sign the Recovery Agreement with the Sole Representative of the Bondholders algoWatt S.p.A., GreenTech Solutions Company listed on the MTA market of Borsa Italiana, announces that, today, Mr. Stefano Neri, as Chairman of the Board of Directors and legal representative of algoWatt, duly authorised by virtue of the resolution adopted by the Board of Directors on 21 June 2021, and Ms. Monica Federici, as Managing Director and legal representative of the parent company Italeaf S.p.A., duly authorized by a resolution of the Board of Directors on 21 June, and Mr. Marzio Molinari, as sole representative of the subscribers of the bond called "Algowatt Tv Eur6m+1.5 Dc27 Amort Eur", listed on the ExtraMOT PRO market, organized and managed by Borsa Italiana S.p.A., duly authorised by virtue of the resolution passed by the Bondholders' Meeting on 30 April 2021 and in compliance with the provisions of the pactum de non petendo signed inter partes on 22 December 2020, on the oth
Supersapiens Powered by Abbott’s Libre Sense Glucose Sport Biosensor Announces Garmin Integration22.6.2021 16:30:00 CEST | Press release
New Connect IQ app gives athletes timely glucose levels on their bike computer and wrist, allowing for real-time adjustments to sustain peak performance Atlanta, GA, USA, June 22, 2021 (GLOBE NEWSWIRE) -- Supersapiens, powered by Abbott’s Libre Sense Glucose Sport Biosensor, is announcing its initial integration of the Supersapiens Connect IQ app with Garmin®. The Supersapiens training ecosystem empowers athletes to optimize fueling, maximize training, and increase performance gains. The integration will provide select users with a compatible Garmin smartwatch or Edge® cycling computer with real-time glucose visibility allowing them to go faster longer. The Supersapiens app can be downloaded now from the Connect IQ™ store. A partnership with global healthcare leader Abbott makes Supersapiens the only energy management ecosystem that directly integrates with a Bluetooth-enabled sports continuous glucose monitor (CGM) — the Abbott Libre Sense Glucose Sport Biosensor. Supersapiens offers
Painter 2022: Must-Have Upgrade for Professional Artists Delivers a Faster, More Powerful Digital Painting Experience22.6.2021 15:01:00 CEST | Press release
Offering unprecedented performance, a streamlined workflow, and improved layer productivity, Painter 2022 makes it easier than ever for artists to create exceptional work OTTAWA, June 22, 2021 (GLOBE NEWSWIRE) -- Painter 2022 responds to users’ top requests and delivers a must-have upgrade by expanding creative possibilities. Designed for Windows 10 and macOS, this powerful and creative digital painting software adds enhancements that focus on accelerating workflows, boosting brush performance, and improving layer productivity to offer a game-changing digital art studio for today’s professional and aspiring artists. “We know the critical role Painter plays in professional artists’ workflows and are honored to be part of the creative process of bringing some of pop culture's most iconic movies, characters and games to life,” said Chris Pierce, Director of Product for Photo and Digital Arts at Corel. “With this version we focused on our customers’ top requests and whether it’s improvemen
IMCD N.V. shareholders adopt all resolutions at AGM22.6.2021 13:55:00 CEST | Press release
ROTTERDAM, The Netherlands (22 June 2021) – IMCD N.V. (hereafter “IMCD” or the “Company”) announces that all resolutions proposed to the shareholders at the Company’s Annual General Meeting (“AGM”) held today were adopted. This includes the adoption of the financial statements for the year 2020 and approval of the dividend proposal of EUR 1.02 per share in cash. The dividend calendar is as follows: Thursday 24 June 2021 - Ex-dividend date Friday 25 June 2021 - Record date Monday 28 June 2021 - Payment date Further resolutions included the reappointment of Deloitte Accountants B.V. as external auditor for the year 2021. The 2020 Remuneration Report received a positive advisory vote with over 94% of voted casted in favor of the report. Details of the Annual General Meeting, including the voting results, are available at IMCD’s corporate website. Attached, please find the press release in pdf format. Attachment PR_IMCD 2021 AGM resolutions
About making of a mandatory share buy-back offer22.6.2021 13:25:00 CEST | Press release
Joint stock company “Olainfarm”, hereinafter referred to as - “the Company”, hereby informs that on the 22nd of June, 2021 Joint stock company “AS “AB CITY””, registration number 40203174414, according to the clause 1 of the article 73 of the Financial Instrument Market Law, informed the Board of the Company about making of a mandatory share buy-back offer. The Board of the joint stock company “Olainfarm” will prepare conclusion and announce its opinion about the offer within terms set by the Financial Instrument Market Law after an advertisement regarding making of a share buy-back offer is published. Additional information: Jānis Dubrovskis Investor Relations Advisor of JSC Olainfarm Phone: +371 29178878 Email: firstname.lastname@example.org
Verisk’s AIR Updates Its Terrorism Model to More Comprehensively Model Damage from Conventional Bomb Blast Attacks22.6.2021 12:11:00 CEST | Press release
BOSTON, June 22, 2021 (GLOBE NEWSWIRE) -- Catastrophe modeling firm AIR Worldwide announced that it has updated its Terrorism Model for the United States to more comprehensively model the extent of damage from conventional bomb blast attacks. Starting with the size and location of the bomb, the model propagates the appropriate blast intensity within a built environment from the exterior to the interior of buildings to yield damage and loss estimates, including property damage and workers’ compensation, and personal injury. AIR Worldwide is a Verisk (Nasdaq:VRSK) business. “When terrorists use conventional weapons—the effects of which tend to be highly localized—they are likely to be targeting specific buildings or facilities,” said Tao Lai, vice president, research, AIR Worldwide. “The amount of damage that occurs at or near the site of an attack depends on a wide variety of factors. In addition to the type of weapon used, the surrounding buildings, building dimensions and blast intens
RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS22.6.2021 11:07:00 CEST | Press release
RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS Auction date2021-06-22Loan2311 Coupon1.00 %ISIN-codeSE0010948240Maturity2023-11-13 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln2,020Volume bought, SEK mln500Number of bids6Number of accepted bids2Average yield0.034 %Lowest accepted yield0.033 %Highest yield0.034 %% accepted at lowest yield 56.82 Auction date2021-06-22 Loan2505 Coupon1.00 %ISIN-codeSE0011414010Maturity2025-05-12 Tendered volume, SEK mln1,000 +/- 500 Volume offered, SEK mln3,000Volume bought, SEK mln1,000Number of bids8Number of accepted bids1Average yield0.219 %Lowest accepted yield0.219 %Highest yield0.219 %% accepted at lowest yield 100.00 Auction date2021-06-22 Loan2805 Coupon0.75 %ISIN-codeSE0015660139Maturity2028-05-12 Tendered volume, SEK mln750 +/- 350 Volume offered, SEK mln1,000Volume bought, SEK mln750Number of bids3Number of accepted bids1Average yield0.623 %Lowest accepted yield0.623 %Highest yield0.623 %% accepted at lowest yield 100.00